

Glucosyloxybenzyl 2-Isobutylmalates from the Tubers of *Gymnadenia conopsea*¹

Toshio Morikawa, Haihui Xie, Hisashi Matsuda, and Masayuki Yoshikawa*

Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto 607-8412, Japan

Received October 12, 2005


Seven new glucosyloxybenzyl 2-isobutylmalates, gymnosides I–VII (1–7), were isolated from the tubers of *Gymnadenia conopsea*. The structures of 1–7 were determined on the basis of chemical and physicochemical evidence.

Gymnadenia conopsea R. Br., an Orchidaceae perennial herb, is widely distributed in the northern parts of China such as Hebei, Liaoning, and Gansu Provinces. The tubers of this herb have been used in traditional Chinese medicine for the treatment of asthma, neurasthenia, and chronic hepatitis.² Recently, we found that the MeOH extract of this natural medicine showed antiallergic activity in the passive cutaneous anaphylaxis (PCA) reactions in mice.³ In the course of our characterization studies on bioactive constituents from Chinese natural medicines,^{1,4–10} we previously reported the structures of three dihydrophenanthrenes, gymconopins A–C, and a dihydrostilbene, gymconopin D, as the less polar constituents from the tubers of *G. conopsea*, together with 10 known constituents and their inhibitory activities on antigen-induced degranulation in RBL-2H3 cells.³ As a continuing study of this natural medicine, we additionally isolated seven new glycosyloxybenzyl 2-isobutylmalates named gymnosides I–VII (1–7). This paper deals with the isolation and elucidation of absolute configuration of the glycosides 1–7.

Results and Discussion

The tubers of *G. conopsea* were extracted with MeOH under reflux. The MeOH extract was subjected to Diaion HP-20 column chromatography to give H₂O-, MeOH-, and acetone-eluted fractions. The MeOH-eluted fraction was subjected to ordinary and reversed-phase silica gel column chromatography and finally HPLC to furnish gymnosides I (1, 0.0024% from the natural medicine), II (2, 0.0009%), III (3, 0.017%), IV (4, 0.0006%), V (5, 0.0014%), VI (6, 0.0021%), and VII (7, 0.0025%), together with dactylorhin A¹¹ (8, 0.12%) and militarine¹¹ (9, 0.072%). Gymnoside I (1) was obtained as a white powder and exhibited a negative specific rotation ($[\alpha]_D^{24}$ –28.0 in MeOH). In the UV spectrum of 1, absorption maxima were observed at 223 (log ϵ 4.10) and 256 (3.20) nm. The IR spectrum of 1 showed absorption bands at 1736, 1710, 1615, 1590, 1514, and 1233 cm⁻¹ assignable to ester carbonyl and carboxyl functions and an aromatic ring in addition to strong absorption bands at 3410 and 1075 cm⁻¹ suggestive of a glycoside moiety. In the positive- and negative-ion FABMS of 1, quasimolecular ions were observed at m/z 481 [M + Na]⁺ and 457 [M – H]⁻, and HRFABMS analysis revealed the molecular formula of 1 to be C₂₁H₃₀O₁₁. The acid hydrolysis of 1 with 1.0 M HCl liberated D-glucose, which was identified by HPLC analysis using an optical rotation detector.^{1,4,6–8,10} The ¹H (pyridine-*d*₅, Table 1) and ¹³C NMR (Table 2) spectra of 1, which were assigned by various NMR experiments,¹² showed signals assignable to two methyls [δ 0.95, 1.03 (3H each, both d, J = 6.7 Hz, H₃-7, 8)], three methylenes [δ 1.90, 1.93 (1H each, both dd, J = 6.1, 14.0 Hz, H₂-5), 3.11, 3.37 (1H each, both d, J = 15.9 Hz, H₂-3), 5.36, 5.39 (1H each, both d, J = 12.2 Hz, H₂-7')], a methine [δ 2.12 (1H, m, H-6)], and an A₂B₂ type aromatic pattern [δ 7.32, 7.47 (2H each, both d, J = 8.5 Hz, H-3',5', 2',6')], together with a β -glucopyranosyl moiety [δ 5.61

Chart 1



* To whom correspondence should be addressed. Tel: +81-75-595-4633. Fax: +81-75-595-4768. E-mail: shoyaku@mb.kyoto-phu.ac.jp.




Figure 1.

Table 1. ^1H NMR (500 MHz, pyridine- d_5) Data of Gymnosides I (1) and II (2)

H	1		2	
	δ (J Hz)	HMBC	δ (J Hz)	HMBC
3	3.11 (d, 15.9) 3.37 (d, 15.9)	C-1,4,5	3.10 (d, 15.0) 3.40 (d, 15.0)	C-1,4,5
5	1.90 (dd, 6.1,14.0) 1.93 (dd, 6.1,14.0)	C-1,3,7,8	1.94 (dd, 6.1,14.0) 2.05 (dd, 6.1,14.0)	C-1,3,7,8
6	2.12 (m)	C-2,5,7,8	2.21 (m)	C-2
7	0.95 (d, 6.7) ^a	C-5,8	1.05 (d, 6.7) ^a	C-5,8
8	1.03 (d, 6.7) ^a	C-5,7	1.08 (d, 6.7) ^a	C-5,7
2',6'	7.47 (d, 8.5)	C-4',7'		
3',5'	7.32 (d, 8.5)	C-1'		
7'	5.36 (d, 12.2) 5.39 (d, 12.2)	C-1,2',6'		
2'',6''			7.35 (d, 8.9)	C-4'',7''
3'',5''			7.27 (d, 8.9)	C-1''
7''			5.13 (d, 12.2) 5.18 (d, 12.2)	C-4,2'',6''
4'-O-Glc-1	5.61 (d, 7.6)	C-4'		
2	4.31 (dd, 7.6,8.9)			
3	4.37 (m)			
4	4.36 (m)			
5	4.10 (m)			
6	4.40 (dd, 5.2,11.9) 4.52 (dd, 2.1,12.2)			
4''-O-Glc-1			5.60 (d, 7.6)	C-4''
2			4.31 (dd, 7.6,9.5)	
3			4.37 (m)	
4			4.36 (m)	
5			4.11 (m)	
6			4.41 (dd, 5.2,12.2) 4.54 (dd, 2.5,12.2)	

^a May be interchanged within the same column.

(1H, d, $J = 7.6$ Hz, H-4'-O-Glc-1)]. The enzymatic hydrolysis of **1** with β -glucosidase gave (2R)-hydroxy-2-(2-methylpropyl)butanedioic acid¹¹ [**1b** = (2R)-2-isobutylmalic acid], which was deduced to be formed via the *p*-hydroxybenzyl ester (**1a**). Compound **1b** was also obtained by the enzymatic hydrolysis of **1** with tannase, which is known to hydrolyze the ester bond of aromatic compounds such as tannins, flavonoids, and chromones.^{13,14} In the HMBC experiment of **1**, long-range correlations were observed between the following proton and carbon pairs: H-3 and C-1, 4, 5; H₂-5 and C-1, 3, 7, 8; H-6 and C-2, 5, 7, 8; H₃-7 and C-5, 8; H₃-8 and C-5, 7; H-2',6' and C-4', 7'; H-3',5' and C-1'; H₂-7' and C-1, 1', 2',6'; H-4'-O-Glc-1 and C-4' (Table 1, Figure S1). Thus the positions of the β -glucopyranosyl and *p*-hydroxybenzyl alcohol moieties in **1** were clarified. On the basis of those findings, the structure of gymnoside I was determined to be 1-(4- β -D-glucopyranosyloxybenzyl)-(2R)-2-isobutylmalate (**1**). Gymnoside II (**2**) was also isolated as a white powder with negative specific rotation ($[\alpha]_{\text{D}}^{25} -21.8$ in MeOH). The UV spectrum of **2** showed absorption maxima at 223 (log ϵ 4.10) and 257 (3.31) nm. The IR spectrum of **2** showed absorption bands at 3432, 1734, 1719, 1617, 1592, 1514, 1235, and 1076 cm^{-1} ascribable to hydroxyl, ester carbonyl, carboxyl, and ether functions and an aromatic ring. The molecular formula $\text{C}_{21}\text{H}_{30}\text{O}_{11}$ of **2**, which was the same as **1**, was determined by the quasimolecular ion peaks in positive- and negative-ion FABMS and by HRFABMS. The acid hydrolysis of **2** with 1.0 M

Table 2. ^{13}C NMR (125 MHz, pyridine- d_5) Data of Gymnosides I (1) and II (2)

C	1	2
1	176.0 (s)	178.5 (s)
2	76.2 (s)	75.9 (s)
3	46.1 (t)	45.9 (t)
4	173.8 (s)	170.9 (s)
5	48.5 (t)	48.6 (t)
6	24.4 (d)	24.7 (d)
7	23.8 (q) ^a	23.0 (q) ^a
8	24.7 (q) ^a	24.8 (q) ^a
1'	130.0 (s)	
2',6'	130.4 (d)	130.4 (s)
3',5'	116.8 (d)	130.2 (d)
4'	158.5 (s)	116.8 (d)
7'	66.9 (t)	158.4 (s)
1''		66.1 (t)
2'',6''		
3'',5''		
4''		
7''		
4'-O-Glc-1	102.0 (d)	
2	74.9 (d)	
3	78.5 (d)	
4	71.2 (d)	
5	78.8 (d)	
6	62.3 (t)	
4''-O-Glc-1		102.0 (d)
2		74.9 (d)
3		78.5 (d)
4		71.2 (d)
5		78.9 (d)
6		62.3 (t)

^a May be interchanged within the same column.

HCl liberated D-glucose, which was identified by HPLC analysis using an optical rotation detector.^{1,4,6-8,10} The proton and carbon signals in the ^1H (pyridine- d_5 , Table 1) and ^{13}C NMR (Table 2) spectra¹² of **2** were very similar to those of **1** {two methyls [δ 1.05, 1.08 (3H each, both d, $J = 6.7$ Hz, H₃-7, 8)], three methylenes [δ 1.94, 2.05 (1H each, both dd, $J = 6.1, 14.0$ Hz, H₂-5), 3.10, 3.40 (1H each, both d, $J = 15.0$ Hz, H₂-3), 5.13, 5.18 (1H each, both d, $J = 12.2$ Hz, H₂-7'')], a methine [δ 2.21 (1H, m, H-6)], and an A₂B₂ type aromatic pattern [δ 7.27, 7.35 (2H each, both d, $J = 8.9$ Hz, H-3'',5'', 2'',6'')], together with a β -glucopyranosyl moiety [δ 5.60 (1H, d, $J = 7.6$ Hz, H-4''-O-Glc-1)]}. The enzymatic hydrolysis of **2** with β -glucosidase or tannase gave **1b** via **2a** (vide ante). The positions of the β -D-glucopyranosyl and *p*-hydroxybenzyl alcohol moieties in **2** were confirmed by the HMBC experiment, which showed long-range correlations between the following proton and carbon pairs: H-3 and C-1, 4, 5; H₂-5 and C-1, 3, 7, 8; H-6 and C-2, 5, 7, 8; H₃-7 and C-5, 8; H₃-8 and C-5, 7; H-2',6' and C-4', 7'; H-3',5' and C-1'; H₂-7' and C-1, 1', 2',6'; H-4'-O-Glc-1 and C-4' (Table 1, Figure S1). Consequently, the structure of gymnoside II was determined as 4-(4- β -D-glucopyranosyloxybenzyl)-(2R)-2-isobutylmalate (**2**).

Gymnoside III (**3**) was isolated as a white powder with negative specific rotation ($[\alpha]_{\text{D}}^{25} -47.6$ in MeOH). The positive- and negative-ion FABMS of **3** showed quasimolecular ions at m/z 953 [$\text{M} + \text{Na}]^+$ and m/z 929 [$\text{M} - \text{H}]^-$. The molecular formula




Figure 2.

(Nippon Rensui Co., Tokyo, Japan), Chromatorex ODS DM1020T (Fuji Silysia Chemical, Ltd., Aichi, Japan, 100–200 mesh); TLC, precoated TLC plates with silica gel 60F₂₅₄ (Merck, 0.25 mm) (normal-phase) and silica gel RP-18 F_{254S} (Merck, 0.25 mm) (reversed-phase); reversed-phase HPLC, precoated TLC plates with silica gel RP-18 F_{254S} (Merck, 0.25 mm); detection was achieved by spraying with 1% Ce(SO₄)₂–10% aqueous H₂SO₄, followed by heating.

Plant Material. Reported before.³

Extraction and Isolation. The dried tubers of *G. conopsea* (12.0 kg) were powdered and extracted three times with MeOH under reflux for 3 h. Evaporation of the solvent under reduced pressure provided a MeOH extract (930 g, 7.8% from the dried tubers). The MeOH extract (307 g) was subjected to Diaion HP-20 column chromatography [3.0 kg, H₂O–MeOH–acetone] to give H₂O-, MeOH-, and acetone-eluted fractions (251, 51, and 5 g, respectively). Normal-phase silica gel column chromatography [1.4 kg, *n*-hexane–EtOAc (5:1–1:1, v/v) to CHCl₃–MeOH–H₂O (10:3:1–7:3:1, lower layer 6:4:1)–MeOH] of the MeOH-eluted fraction (45.5 g) gave 10 fractions [1 (1.82 g), 2 (1.03 g), 3 (0.40 g), 4 (0.95 g), 5 (1.35 g), 6 (3.34 g), 7 (6.59 g), 8 (21.36 g), 9 (6.79 g), and 10 (1.87 g)]. From fractions 3–5, phenanthrenes and stilbenes were isolated.³ Fraction 6 (3.34 g) was subjected to reversed-phase silica gel column chromatography [100 g, MeOH–H₂O (20:80–30:70–50:50, v/v) to MeOH] to give six fractions [6-1 (920 mg), 6-2 (384 mg), 6-3 (352 mg), 6-4 (772 mg), 6-5 (280 mg), and 6-6 (632 mg)]. Fraction 6-4 (772 mg) was further purified by HPLC [YMC-Pack ODS-A (20 × 250 mm), MeOH–H₂O (40:60, v/v)] to give gymnosides I (1, 85 mg, 0.0024%) and II (2, 33 mg, 0.0009%). Fraction 7 (6.59 g) was subjected to reversed-phase silica gel column chromatography [210 g, MeOH–H₂O (10:90–30:70–50:50–70:30, v/v) to MeOH] to give seven fractions [7-1 (1070 mg), 7-2 (370 mg), 7-3 (3260 mg), 7-4 (190 mg), 7-5 (380 mg), 7-6 (840 mg), and 7-7 (480 mg)]. Fraction 7-3 (710 mg) was subjected to HPLC [MeOH–H₂O (50:50, v/v)] to give militarine (9, 557 mg, 0.072%). Fraction 7-6 (0.84 g) was further purified by HPLC [MeOH–H₂O (65:35, v/v)] to give gymnosides IV (4, 23 mg, 0.0006%), V (5, 47 mg, 0.0014%), VI (6, 14 mg, 0.0004%), and VII (7, 89 mg, 0.0025%). Fraction 8 (21.36 g) was subjected to reversed-phase silica gel column chromatography [630 g, MeOH–H₂O (10:90–20:80–30:70–60:40–50:50–70:30, v/v) to MeOH] to give nine fractions [8-1 (4.24 g), 8-2 (3.26 g), 8-3 (4.17 g), 8-4 (4.71 g), 8-5 (1.05 g), 8-6 (0.29 g), 8-7 (0.44 g), 8-8 (0.13 g), and 8-9 (3.07 g)]. Fraction 8-3 (0.27 g) was subjected to HPLC [MeOH–H₂O (45:55, v/v)] to give dactylorhin A (8, 229 mg, 0.11%). Fraction 8-5 (1.05 g) was subjected to HPLC [MeOH–H₂O (50:50, v/v)] to give gymnoside III (3, 595 mg, 0.017%) and 8 (78 mg, 0.0022%). Fraction 8-8 (0.13 g) was further purified by HPLC [MeOH–H₂O (65:35, v/v)] to give 6 (62 mg, 0.0017%). Dactylorhin A (8) and militarine (9) were identified by comparison of the physical data ([α]_D, UV, IR, ¹H and ¹³C NMR, MS) with reported values.¹¹

Gymnoside I (1): white powder, [α]_D²⁴ –28.0 (*c* 3.52, MeOH); UV (MeOH) λ_{\max} (log ϵ) 223 (4.10), 256 (3.20); IR (KBr) ν_{\max} 3410, 2957, 1736, 1710, 1615, 1590, 1514, 1233, 1075 cm⁻¹; ¹H NMR data, see Table 1; ¹³C NMR data, see Table 2; positive-ion FABMS *m/z* 481 [M + Na]⁺; negative-ion FABMS *m/z* 457 [M – H]⁻; HRFABMS *m/z* 481.1694 (calcd for C₂₁H₃₀O₁₁Na [M + Na]⁺, 481.1686).

Gymnoside II (2): white powder, [α]_D²⁴ –21.8 (*c* 0.98, MeOH); UV (MeOH) λ_{\max} (log ϵ) 223 (4.10), 257 (3.31); IR (KBr) ν_{\max} 3432, 2957, 1734, 1719, 1617, 1592, 1514, 1235, 1076 cm⁻¹; ¹H NMR data, see Table 1; ¹³C NMR data, see Table 2; positive-ion FABMS *m/z* 481 [M + Na]⁺; negative-ion FABMS *m/z* 457 [M – H]⁻; HRFABMS *m/z* 481.1691 (calcd for C₂₁H₃₀O₁₁Na [M + Na]⁺, 481.1686).

Gymnoside III (3): white powder, [α]_D²² –47.6 (*c* 2.19, MeOH); UV (MeOH) λ_{\max} (log ϵ) 224 (4.36), 271 (3.28); IR (KBr) ν_{\max} 3432, 2957, 1736, 1613, 1592, 1514, 1287, 1075 cm⁻¹; ¹H NMR data, see Table 3; ¹³C NMR data, see Table 4; positive-ion FABMS *m/z* 953 [M + Na]⁺; negative-ion FABMS *m/z* 929 [M – H]⁻; HRFABMS *m/z* 953.3258 (calcd for C₄₂H₅₈O₂₃Na [M + Na]⁺, 953.3267).

Gymnoside IV (4): white powder, [α]_D²⁵ –20.2 (*c* 1.32, MeOH); UV (MeOH) λ_{\max} (log ϵ) 223 (4.57), 278 (4.37); IR (KBr) ν_{\max} 3432, 2928, 1734, 1636, 1613, 1514, 1233, 1075 cm⁻¹; ¹H NMR data, see Table 3; ¹³C NMR data, see Table 4; positive-ion FABMS *m/z* 1041 [M + Na]⁺; negative-ion FABMS *m/z* 1017 [M – H]⁻; HRFABMS *m/z* 1041.3574 (calcd for C₄₉H₆₂O₂₃Na [M + Na]⁺, 1041.3580).

Gymnoside V (5): white powder, [α]_D²⁷ –11.6 (*c* 1.61, MeOH); UV (MeOH) λ_{\max} (log ϵ) 223 (4.56), 278 (4.36); IR (KBr) ν_{\max} 3432, 2955, 1736, 1638, 1613, 1514, 1458, 1232, 1075 cm⁻¹; ¹H NMR data, see Table 3; ¹³C NMR data, see Table 4; positive-ion FABMS *m/z* 1041 [M + Na]⁺; negative-ion FABMS *m/z* 1017 [M – H]⁻; HRFABMS *m/z* 1041.3582 (calcd for C₄₉H₆₂O₂₃Na [M + Na]⁺, 1041.3580).

Gymnoside VI (6): white powder, [α]_D²⁵ –45.1 (*c* 2.74, MeOH); UV (MeOH) λ_{\max} (log ϵ) 223 (4.51), 278 (4.29); IR (KBr) ν_{\max} 3432, 2957, 1736, 1638, 1514, 1451, 1233, 1075 cm⁻¹; ¹H NMR data, see Table 3; ¹³C NMR data, see Table 4; positive-ion FABMS *m/z* 1041 [M + Na]⁺; negative-ion FABMS *m/z* 1017 [M – H]⁻; HRFABMS *m/z* 1041.3574 (calcd for C₄₉H₆₂O₂₃Na [M + Na]⁺, 1041.3580).

Gymnoside VII (7): white powder, [α]_D¹⁹ –12.0 (*c* 0.78, MeOH); UV (MeOH) λ_{\max} (log ϵ) 223 (4.49), 278 (4.28); IR (KBr) ν_{\max} 3432, 2926, 1736, 1638, 1613, 1514, 1235, 1075 cm⁻¹; ¹H NMR data, see Table 3; ¹³C NMR data, see Table 4; positive-ion FABMS *m/z* 1083 [M + Na]⁺; negative-ion FABMS *m/z* 1059 [M – H]⁻; HRFABMS *m/z* 1083.3676 (calcd for C₅₁H₆₄O₂₄Na [M + Na]⁺, 1083.3685).

Acid Hydrolysis of 1–7. A solution of 1–7 (each 1.5 mg) in 1 M HCl (2.0 mL) was heated under reflux for 3 h. After cooling, the reaction mixture was extracted with EtOAc. The aqueous layer was subjected to HPLC analysis under the following conditions, respectively: HPLC column, Kaseisorb LC NH₂-60-5, 4.6 mm i.d. × 250 mm (Tokyo Kasei Co., Ltd., Tokyo, Japan); detection, optical rotation [Shodex OR-2 (Showa Denko Co., Ltd., Tokyo, Japan)]; mobile phase, CH₃CN–H₂O (75:25, v/v); flow rate 0.8 mL/min]. Identification of D-glucose in the aqueous layer was carried out by comparison of its retention time and specific rotation with those of an authentic sample, *t*_R: 12.3 min (D-glucose, positive specific rotation).

Enzymatic Hydrolysis of 1–7 with β -Glucosidase. A solution of 1 or 2 (5.5 mg each, both 0.012 mmol) in H₂O (2.0 mL) was treated with β -glucosidase (5.0 mg, from Almond, Oriental Yeast Co., Ltd., Tokyo, Japan), and the solution was stirred at 37 °C for 24 h. After EtOH was added, the solvent was removed under reduced pressure and the residue was purified by HPLC [MeOH–1% aqueous HOAc (45:

55, v/v] to furnish (2*R*)-hydroxy-2-(2-methylpropyl)butanedioic acid¹¹ (**1b**, 1.8 mg, 79% from **1**; 1.7 mg, 71% from **2**), respectively. Through a similar procedure, a solution of **3** (7.5 mg, 0.008 mmol), **4** (7.0 mg, 0.007 mmol), **5** (7.0 mg, 0.007 mmol), **6** (9.4 mg, 0.009 mmol), or **7** (8.8 mg, 0.008 mmol) in H₂O (2.0 mL) was treated with β -glucosidase (5.0 mg), and the solution was stirred at 37 °C for 24 h. Workup as above gave a residue, which was purified by HPLC [MeOH–1% aqueous HOAc (45:55, v/v)] to give **3a** (1.8 mg, 57% from **3**), **4a** (2.6 mg, 79% from **4**), **5a** (2.3 mg, 70% from **5**), **6a** (2.7 mg, 61% from **6**), and **7a** (2.4 mg, 55% from **7**), respectively.

Compound 3a: white powder, $[\alpha]^{15}_D$ –17.8 (*c* 0.11, MeOH); UV (MeOH) λ_{max} (log ϵ) 256 (4.14); IR (KBr) ν_{max} 3423, 1736, 1718, 1619, 1509, 1458, 1248, 1090 cm⁻¹; ¹H NMR data, see Table 5; ¹³C NMR (125 MHz, pyridine-*d*₅) δ_C 177.6 (C-1), 81.4 (C-2), 44.2 (C-3), 173.8 (C-4), 49.4 (C-5), 24.6 (C-6), 24.2 (C-7), 24.8 (C-8), 100.4 (Glc-1), 76.0 (Glc-2), 79.2 (Glc-3), 71.0 (Glc-4), 75.1 (Glc-5), 64.5 (Glc-6), 20.8 (–OCOCH₃), 171.0 (–OCOCH₃); positive-ion FABMS *m/z* 417 [M + Na]⁺; HRFABMS *m/z* 417.1367 (calcd for C₁₆H₂₆O₁₁Na [M + Na]⁺, 417.1373).

Compound 4a: white powder, $[\alpha]^{24}_D$ –22.6 (*c* 0.20, MeOH); UV (MeOH) λ_{max} (log ϵ) 218 (4.35), 276 (4.28); IR (KBr) ν_{max} 3423, 2962, 1719, 1636, 1509, 1456, 1076 cm⁻¹; ¹H NMR data, see Table 5; ¹³C NMR (125 MHz, pyridine-*d*₅) δ_C 177.6 (C-1), 80.7 (C-2), 44.2 (C-3), 173.8 (C-4), 48.8 (C-5), 24.6 (C-6), 24.4 (C-7), 24.8 (C-8), 100.5 (Glc-1), 73.8 (Glc-2), 80.7 (Glc-3), 68.8 (Glc-4), 78.2 (Glc-5), 62.0 (Glc-6), 135.1 (Cin-1), 128.4 (Cin-2,6), 129.2 (Cin-3,5), 130.6 (Cin-4), 144.5 (Cin-7), 119.7 (Cin-8), 167.2 (Cin-9); positive-ion FABMS *m/z* 505 [M + Na]⁺; HRFABMS *m/z* 505.1692 (calcd for C₂₃H₃₀O₁₁Na [M + Na]⁺, 505.1686).

Compound 5a: white powder, $[\alpha]^{23}_D$ –22.4 (*c* 0.15, MeOH); UV (MeOH) λ_{max} (log ϵ) 217 (4.42), 278 (4.35); IR (KBr) ν_{max} 3432, 2962, 1718, 1638, 1509, 1455, 1078 cm⁻¹; ¹H NMR data, see Table 5; ¹³C NMR (125 MHz, pyridine-*d*₅) δ_C 177.7 (C-1), 81.3 (C-2), 44.3 (C-3), 173.9 (C-4), 49.0 (C-5), 24.6 (C-6), 24.3 (C-7), 24.8 (C-8), 100.4 (Glc-1), 76.1 (Glc-2), 76.8 (Glc-3), 72.4 (Glc-4), 76.2 (Glc-5), 62.1 (Glc-6), 134.9 (Cin-1), 128.6 (Cin-2,6), 129.2 (Cin-3,5), 130.7 (Cin-4), 145.1 (Cin-7), 119.0 (Cin-8), 166.5 (Cin-9); positive-ion FABMS *m/z* 505 [M + Na]⁺; HRFABMS *m/z* 505.1692 (calcd for C₂₃H₃₀O₁₁Na [M + Na]⁺, 505.1686).

Compound 6a: white powder, $[\alpha]^{27}_D$ –24.8 (*c* 0.11, MeOH); UV (MeOH) λ_{max} (log ϵ) 217 (4.20), 277 (4.30); IR (KBr) ν_{max} 3432, 2962, 1719, 1638, 1509, 1458, 1078 cm⁻¹; ¹H NMR data, see Table 5; ¹³C NMR (125 MHz, pyridine-*d*₅) δ_C 177.6 (C-1), 81.4 (C-2), 44.2 (C-3), 173.9 (C-4), 49.3 (C-5), 24.6 (C-6), 24.2 (C-7), 24.8 (C-8), 100.5 (Glc-1), 76.0 (Glc-2), 79.3 (Glc-3), 71.1 (Glc-4), 75.2 (Glc-5), 64.7 (Glc-6), 135.0 (Cin-1), 128.6 (Cin-2,6), 129.2 (Cin-3,5), 130.5 (Cin-4), 144.8 (Cin-7), 119.1 (Cin-8), 167.1 (Cin-9); positive-ion FABMS *m/z* 505 [M + Na]⁺; HRFABMS *m/z* 505.1682 (calcd for C₂₃H₃₀O₁₁Na [M + Na]⁺, 505.1686).

Compound 7a: white powder, $[\alpha]^{27}_D$ –21.5 (*c* 0.12, MeOH); UV (MeOH) λ_{max} (log ϵ) 217 (4.21), 276 (4.31); IR (KBr) ν_{max} 3432, 2957, 1731, 1638, 1509, 1451, 1246, 1086 cm⁻¹; ¹H NMR data, see Table 5; ¹³C NMR (125 MHz, pyridine-*d*₅) δ_C 177.4 (C-1), 81.8 (C-2), 44.2 (C-3), 173.7 (C-4), 49.2 (C-5), 24.7 (C-6), 24.3 (C-7), 24.7 (C-8), 100.3 (Glc-1), 73.9 (Glc-2), 80.3 (Glc-3), 69.4 (Glc-4), 74.9 (Glc-5), 64.2 (Glc-6), 20.8 (–OCOCH₃), 170.1 (–OCOCH₃), 135.0 (Cin-1), 128.5 (Cin-2,6), 129.2 (Cin-3,5), 130.5 (Cin-4), 144.7 (Cin-7), 119.5 (Cin-8), 166.8 (Cin-9); positive-ion FABMS *m/z* 547 [M + Na]⁺; HRFABMS *m/z* 547.1796 (calcd for C₂₅H₃₂O₁₂Na [M + Na]⁺, 547.1791).

Enzymatic Hydrolysis of 1–7 with Tannase. A solution of **1** (5.7 mg, 0.012 mmol) or **2** (5.1 mg, 0.011 mmol) in H₂O (2.0 mL) was treated with tannase (3.5 mg, from *Aspergillus oryzae*, Wako Pure Chemical Ind., Ltd., Osaka, Japan), and the solution was stirred at 37 °C for 24 h. After EtOH was added, the solvent was removed under reduced pressure and the residue was purified by HPLC [MeOH–1% aqueous HOAc (45:55, v/v)] to furnish **1b**¹¹ (2.0 mg, 85% from **1**, 1.6 mg, 76% from **2**). Through a similar procedure, a solution of **3** (10.1 mg, 0.011 mmol), **4** (6.1 mg, 0.006 mmol), **5** (7.0 mg, 0.007 mmol), **6** (9.8 mg, 0.010 mmol), or **7** (10.0 mg, 0.009 mmol) in H₂O (2.0 mL) was treated with tannase (5.0 mg), and the solution was stirred at 37 °C for 24 h. Workup as above gave a residue, which was purified by HPLC [MeOH–1% aqueous HOAc (45:55 or 50:50 v/v)] to furnish **3a** (2.8 mg, 66% from **3** or 2.4 mg, 65% from **7**), dactylirhin C (**4b**), 1.5 mg, 72% from **4**, 1.6 mg, 66% from **5**, or 2.4 mg, 71% from **6**,

and *trans*-cinnamic acid (0.7 mg, 80% from **4**, 0.7 mg, 70% from **5**, or 1.0 mg, 72% from **6** or 1.0 mg, 73% from **7**).

Acetylation of 3a and 4b. A solution of **3a** (2.3 mg, 0.006 mmol) in pyridine (1.0 mL) was treated with Ac₂O (0.8 mL), and the mixture was stirred at room temperature for 12 h. The reaction mixture was poured into ice–water and extracted with EtOAc. The EtOAc extract was successively washed with 5% HCl, saturated aqueous NaHCO₃, and brine, then dried over MgSO₄ powder and filtered. Removal of the solvent under reduced pressure furnished a residue, which was purified by HPLC [MeOH–1% aqueous HOAc (60:40, v/v)] to give **3b** (2.5 mg, 83%). Through a similar procedure, **3b** (2.7 mg, 87%) was also prepared from **4b** (2.1 mg, 0.006 mmol).

Compound 3b: white powder, $[\alpha]^{23}_D$ –6.7 (*c* 0.14, MeOH); IR (KBr) ν_{max} 2957, 1748, 1368, 1235, 1038 cm⁻¹; ¹H NMR (500 MHz, pyridine-*d*₅) δ 0.91, 1.00 (3H each, both d, *J* = 6.4 Hz, H₃-7, 8), 1.97 (2H, m, H₂-5), 1.99 (1H, m, H-6), 1.91, 2.03, 2.04, 2.04 (3H each, all s, –OCOCH₃), 3.22, 3.60 (1H each, both d, *J* = 17.4 Hz, H₂-3), 4.23 (1H, m, H-5'), 4.93 (1H, dd, *J* = 8.2, 9.2 Hz, H-2'), [4.38 (1H, dd, *J* = 2.0, 12.2 Hz), 4.53 (1H, dd, *J* = 5.2, 12.2 Hz), H₂-6'], 5.58 (1H, dd, *J* = 9.2, 9.8 Hz, H-4'), 6.00 (1H, dd, *J* = 9.8, 9.8 Hz, H-3'), 6.06 (1H, d, *J* = 7.6 Hz, H-1'); ¹³C NMR (125 MHz, pyridine-*d*₅) δ_C 177.6 (C-1), 80.4 (C-2), 45.4 (C-3), 173.7 (C-4), 48.6 (C-5), 24.4 (C-6), 23.7 (C-7), 24.7 (C-8), 94.4 (Glc-1), 77.8 (Glc-2), 72.6 (Glc-3), 69.3 (Glc-4), 73.6 (Glc-5), 62.4 (Glc-6), 20.4, 20.4, 20.5, 20.5 (–OCOCH₃), 170.0, 170.0, 170.4, 170.5 (–OCOCH₃); positive-ion FABMS *m/z* 543 [M + Na]⁺; HRFABMS *m/z* 543.1682 (calcd for C₂₂H₃₂O₁₄Na [M + Na]⁺, 543.1690).

Acknowledgment. Part of this work was supported by the 21st COE Program, Academic Frontier Project, and a Grant-in Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Supporting Information Available: H–H COSY, H–H HOHAHA, and HMBC correlations of gemnosides I–VII (**1–7**) (Figure S1). This information is available free of charge via the Internet at <http://pubs.acs.org>.

References and Notes

- (1) This paper is number 16 in our series Bioactive Constituents from Chinese Natural Medicines. For paper number 15, see: Xie, H.; Wang, T.; Matsuda, H.; Morikawa, T.; Yoshikawa, M.; Tani, T. *Chem. Pharm. Bull.* **2005**, *53*, 1416–1422.
- (2) *Dictionary of Traditional Chinese Medicines*; Shanghai Scientific and Technologic Press, Ed.; Shogakkan: Tokyo, 1985; pp 1185–1186.
- (3) Matsuda, H.; Morikawa, T.; Xie, H.; Yoshikawa, M. *Planta Med.* **2004**, *70*, 847–855.
- (4) Matsuda, H.; Morikawa, T.; Tao, J.; Ueda, K.; Yoshikawa, M. *Chem. Pharm. Bull.* **2002**, *50*, 208–215.
- (5) Morikawa, T.; Matsuda, H.; Toguchida, I.; Ueda, K.; Yoshikawa, M. *J. Nat. Prod.* **2002**, *65*, 1468–1474.
- (6) Tao, J.; Morikawa, T.; Toguchida, I.; Ando, S.; Matsuda, H.; Yoshikawa, M. *Bioorg. Med. Chem.* **2002**, *10*, 4005–4012.
- (7) Morikawa, T.; Tao, J.; Ando, S.; Matsuda, H.; Yoshikawa, M. *J. Nat. Prod.* **2003**, *66*, 638–645.
- (8) Tao, J.; Morikawa, T.; Ando, S.; Matsuda, H.; Yoshikawa, M. *Chem. Pharm. Bull.* **2003**, *51*, 654–662.
- (9) Sun, B.; Morikawa, T.; Matsuda, H.; Tewtrakul, S.; Wu, L. J.; Harima, S.; Yoshikawa, M. *J. Nat. Prod.* **2004**, *67*, 1464–1469.
- (10) Morikawa, T.; Sun, B.; Matsuda, H.; Wu, L. J.; Harima, S.; Yoshikawa, M. *Chem. Pharm. Bull.* **2004**, *52*, 1194–1199.
- (11) Kizu, H.; Kaneko, E.; Tomimori, T. *Chem. Pharm. Bull.* **1999**, *47*, 1618–1625.
- (12) The ¹H and ¹³C NMR spectra of **1–7** and their derivatives were assigned with the aid of DEPT, DQF COSY, HMQC, HMBC, and ¹H–¹H and ¹³C–¹H HOHAHA experiments.
- (13) Yoshida, T.; Tanaka, K.; Chen, X.-M.; Okuda, T. *Chem. Pharm. Bull.* **1989**, *37*, 920–924.
- (14) Ito, H.; Kasajima, N.; Tokuda, H.; Nishino, H.; Yoshida, T. *J. Nat. Prod.* **2004**, *67*, 411–415.
- (15) *trans*-Cinnamic acid was identified by comparison of the physical data (UV, IR, ¹H and ¹³C NMR, MS) with a commercially available sample.